According to Imagion Biosystems (ASX:IBX) CEO, Robert Proulx, advancements in imaging have been slow, with no real progress made for half a century. Imagion is looking to redress that balance and speaks with Finfeed about the cancer diagnostic market, how Imagion is leading the way in bringing the field into the 21st century and why people should seek out early detection treatments, if they feel vulnerable to cancer in any way.